People · Operator
Named in public records as an officer, director or promoter · active 2013–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Genapsys, Inc. | — | Biotechnology | Series B | $106.0M | $870.9M | 2013 |
Fred Nazem at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Fred Nazem on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Zollars | 1 | 5 |
| Jason Myers | 1 | 4 |
| Frank Witney | 1 | 3 |
| Fred F. Nazem | 1 | 2 |
| Hamid Moghadam | 1 | 1 |
| Rakesh Sachdev | 1 | 1 |
| Hesaam Esfandyarpour | 1 | 1 |
| Laurent Bellon | 1 | 1 |
| Cui Xiangmin | 1 | 1 |
| Xiangmin F. Cui | 1 | 1 |
| Harish Soundararajanand | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.